Although messenger RNA (mRNA) was discovered in 1961, it took nearly 30 years for its therapeutic potential to come to light. In 1990 a group at the University of Wisconsin injected RNA expression vectors for the proteins chloramphenicol acetyltransferase, luciferase, and beta-galactosidase into mouse skeletal muscle and detected protein expression “in all cases” with “no special delivery system ... required for these effects.” Moreover, expression levels were comparable to those obtained through transfected fibroblast DNA delivery, which the Wisconsin researchers ran as the control. Researchers reported that protein production was confined to muscle and persisted for at least two months.
Drug discovery and development products Search Now Search our directory to find the discovery-related products for your research needs.
What is IVT mRNA?
In vitro transcribed (IVT) mRNA has recently emerged as a way to harness, for therapeutics or prevention, the protein-producing mechanisms already in place in living cells. IVT mRNAs are synthetic genetic constructs engineered and produced in vitro to express specific proteins in vivo, in patients. Genetic manipulation of IVT mRNAs can address the challenges inherent in therapeutic in vivo transient protein expression, particularly for controlling translational efficiency and the drug’s immunogenicity. As such, IVT mRNA is currently under development for a broad range of treatments and vaccines, for example for mRNA-based cancer immunotherapies, for inducing immunity to infectious diseases, as protein replacement therapies, and even for cell-based (and cell-free) regenerative medicine.
Currently the gold standard for mRNA production, IVT mRNA uses bacteriophage-derived modified RNA polymerases to synthesize mRNA from synthetic or chemically modified ribonucleoside triphosphate moieties (rNTPs). As a manufacturing process, IVT is efficient and robust, but it requires sequence-specific promoters and in many embodiments the composition of terminal regions is unpredictable due to polymerase non-specific run-off.
“The safety and efficacy of IVT mRNA based drugs depends, in part, on the ability to manufacture stable and high-quality IVT mRNAs,” says Kyle Luttgeharm, Ph.D., Product Manager Automated Electrophoresis, Agilent. "With analytical tools such as parallel capillary electrophoresis, the size and purity of IVT mRNAs can be rapidly determined, providing users with information necessary for the production of high-quality IVT mRNAs.”
Among its many advantages as a gene therapy vehicle, IVT mRNA effects transient protein expression and, unlike DNA-based gene therapies, does not need to enter the nucleus for translation to occur. Where DNA-based treatments are captive to the host cell’s nuclear protein-making machinery, IVT mRNA is not. Once mRNA reaches the cytoplasm the protein is expressed and the mRNA degraded in very short order. Mutagenesis should not occur since IVT mRNA is processed before it has the opportunity to enter the nucleus. Because cells process and degrade mRNA rapidly, and mRNA is not taken up in the nucleus, treatments operate only transiently. In theory at least, treatments may be turned off and on, or offered sequentially, within the parameters of mRNA degradation and protein expression, and in accordance with the patient’s response.
More than infectious disease immunity
Global experience with the highly successful mRNA-based COVID immunizations has biased our view of IVT mRNA toward immunology and related applications, for example to prevent infectious diseases or as cancer vaccines. Although most treatment-oriented mRNA research still focuses on immunity in all its manifestations, regenerative medicine is an emerging (and intriguing) application.
Organ, tissue, and cell regeneration has been a hot topic for at least 30 years, with potential applications in the transplantation of whole organs damaged by injury or disease, in tissue (e.g., skin) regeneration, and for the restoration of cellular function (islet cells in type 1 diabetes). Regenerative medicine, however, has been severely limited by its reliance on methods for growing tissues in the lab and transplanting them into patients. The mRNA approach instead instructs organisms to make these complex processes itself through the enhancement of natural mechanisms of repair and tissue regeneration.
They do this through one of three ways, two of which are cell-based. IVT mRNA techniques can now be applied to therapy-worthy cells, either by re-programming somatic cells into induced pluripotent stem cells (iPSCs) or by transferring genes to stem cells. In both instances cellular engineering occurs ex vivo and cells, after further expansion in the laboratory, are re-introduced into patients.
Another class of application includes cell-free strategies, which involves delivering mRNA constructs directly to tissues in living patients to deliver growth or transcription factors that signal somatic cells to assume a desired phenotype, for example to express a protein that is under-expressed due to disease. Several interesting proofs of principle, all in animal models, have recently been reported.
An interdisciplinary group led by researchers at Boston University, for example, have published data on induction of “intrinsic” liver regeneration in mice through transient expression of hepatocyte and epidermal growth factors delivered via lipid nanoparticle-encapsulated mRNA. In this instance the growth factors induced or enhanced the natural ability of liver cells to restore full liver function. Virtually all hepatocytes were transfected, in addition to sub-populations of endothelial and Kupffer cells in this particular mouse model of chronic liver injury for non-alcoholic fatty liver disease. The authors concluded that treatments “sharply reverse steatosis and accelerate restoration of liver function” and “accelerate liver regeneration after acetaminophen-induced acute liver injury with rapid return to baseline ALT levels.”
Similarly, a joint Taiwanese-Japanese group demonstrated the potential for IVT mRNA treatments in accelerating healing in a rat model for intervertebral disk degeneration. Disk degeneration involves both the disintegration of the tissue’s structural components (collagen, glycosaminoglycans, proteoglycans) and dysregulation of the disk matrix resulting in fibrosis. Administering mRNA encoding for a cartilage-anabolic transcription factor maintained disk height (addressing the structural issues) to a greater extent than a sham saline shot, while preventing fibrosis in the disk tissue. In addition, the use of nanomicelle delivery of mRNA reduced treatment-related inflammation, which was observed after “naked” mRNA injections. Investigators concluded that mRNA “has a potential for treating IVD degenerative diseases by introducing a cartilage-anabolic factor into the host cells.”
The discovery of mRNA in 1961 laid the foundation for its therapeutic use, which took nearly 30 years to emerge. Recent advancements in state-of-the-art methodologies have provided new insights into the use of IVT mRNA for various applications, including for regenerative medicine, which looks especially promising.